본문으로 바로가기 주메뉴 바로가기

사용자별 맞춤메뉴

자주찾는 메뉴

추가하기
닫기

연구성과

contents area

detail content area

The association of tumor necrosis factor superfamily 13 with recurrence of immunoglobulin ......
  • 작성일2020-05-07
  • 최종수정일2020-05-07
  • 담당부서연구기획과
  • 연락처043-719-8033
  • 646

BMC Nephrology, 2019. 20(1), 33-, DOI: https://doi.org/10.1186/s12882-019-1222-4


The association of tumor necrosis factor superfamily 13 with recurrence of immunoglobulin A nephropathy in living related+F30:F41 kidney transplantation

Hyung Ah Jo, Seung Seok Han;Sunhwa Lee;Joo Young Kim;Seung Hee Yang;Hajeong Lee;Jae Seok Yang;Jung Pyo Lee;Kwon Wook Joo;Chun Soo Lim;Yon Su Kim;Curie Ahn;Jin Suk Han;Dong Ki Kim


Abstract

    Background: An increasing amount of evidence has demonstrated an association between an increase in the levelof tumor necrosis factor superfamily 13 (TNFSF13) and immunoglobulin A nephropathy (IgAN) progression. We aimedto evaluate if the level of pre-transplant serum TNFSF13 is predictive of IgAN recurrence after kidney transplantation.

    Methods: This analysis was based on the clinical and laboratory data of 69 patients with IgAN who underwent firstkidney transplantation with no evidence of mesangial IgA deposits in zero-time transplantation biopsy. We measuredpre-transplant serum TNFSF13, total IgA, and galactose-deficient IgA1 levels.

    Results: The recurrence rate of IgAN over a median follow-up duration of 5.1 years was 15.9% (11/69 patients), with amean time to the first recurrence of 1.7 years. The high pre-transplant TNFSF13 level was associated withIgAN recurrence after kidney transplantation among patients who received a graft from a living related donor.

    Conclusions: This study highlights association of TNFSF13 levels in recurrent IgAN patients who undergoliving related donor transplantation. Further research is needed to clarify mechanisms by which TNFSF13affects the recurrence of IgA nephropathy.



  • 본 연구는 질병관리본부 연구개발과제연구비를 지원받아 수행되었습니다.
  • This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.


본 공공저작물은 공공누리  출처표시 조건에 따라 이용할 수 있습니다 본 공공저작물은 공공누리 "출처표시" 조건에 따라 이용할 수 있습니다.
TOP